1. Home
  2. GGT vs CRDF Comparison

GGT vs CRDF Comparison

Compare GGT & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gabelli Multi-Media Trust Inc. (The)

GGT

Gabelli Multi-Media Trust Inc. (The)

HOLD

Current Price

$4.23

Market Cap

145.5M

Sector

Finance

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.89

Market Cap

130.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GGT
CRDF
Founded
1994
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
145.5M
130.7M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
GGT
CRDF
Price
$4.23
$1.89
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$9.63
AVG Volume (30 Days)
339.3K
710.7K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
15.56%
N/A
EPS Growth
N/A
27.37
EPS
0.83
N/A
Revenue
N/A
$365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$5.09
N/A
Revenue Growth
N/A
49.61
52 Week Low
$3.75
$1.48
52 Week High
$4.94
$4.56

Technical Indicators

Market Signals
Indicator
GGT
CRDF
Relative Strength Index (RSI) 54.94 49.25
Support Level $4.13 $1.51
Resistance Level $4.29 $2.05
Average True Range (ATR) 0.07 0.12
MACD 0.02 0.06
Stochastic Oscillator 87.27 68.32

Price Performance

Historical Comparison
GGT
CRDF

About GGT Gabelli Multi-Media Trust Inc. (The)

Gabelli Multimedia Trust Inc is a non-diversified closed-end management investment company. Its investment objective is the long-term growth of capital with income as a secondary objective. The fund invests majority of its assets, under normal market conditions, in common stock and other securities, including convertible securities, preferred stock, options, and warrants of companies in the telecommunications, media, publishing, and entertainment industries.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: